Type to search

Industry News News Partnerships

Virpax Pharmaceuticals Expands AnQlar™ Development and Commercialization Rights Through Worldwide Licensing Agreement

Share
Virpax Pharmaceuticals Expands AnQlar™ Development and Commercialization Rights Through Worldwide Licensing Agreement | Pharmtech Focus

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive product candidates for pain management as well as PTSD, CNS disorders and anti-viral indications, expanded its exclusive license agreement for AnQlar™ with Nanomerics Ltd., providing Virpax with the worldwide rights for development and commercialization.

Virpax has completed in-vitro, ex-vivo (human mucosal cells), and in-vivo (rats) studies on AnQlar which demonstrated that AnQlar inhibited viral replication of SARS-CoV-2 and influenza in animals at ranges higher than those encountered in human nasal passages. No adverse effects were observed during the studies. Animal studies also demonstrated decreased levels of the virus in animal brain tissue. Virpax anticipates that Investigational New Drug (IND)-enabling studies will be completed by the fourth fiscal quarter of 2022 and anticipates pursuing a nonprescription drug approval pathway.

“We would like to extend our appreciation to our partner, Nanomerics, in collaborating with the Company to restructure our original agreement, exchanging North American rights with an agreement that awards us global rights and replacing all commercial milestones and royalties with a profit-sharing arrangement. This assists us with the transition of AnQlar to a potential over-the-counter designation by the FDA,” stated Christopher M. Chipman, CFO and Secretary of Virpax.

“Obtaining the worldwide rights to AnQlar is consistent with our global business model and puts the company in a stronger position to pursue strategic alliances or enterprise opportunities for this product candidate,” commented Anthony P. Mack, Chairman & CEO of Virpax. 

Tags:

Next Up